Cigna (CI) Q1 2026 earnings review
Strategic Pivots Pay Off as Specialty and Healthcare Segments Drive Earnings Beat
Cigna delivered a strong Q1 2026, beating expectations and raising its full-year adjusted EPS guidance to at least $30.35. Total adjusted revenues rose 5% YoY to $68.5 billion, and adjusted income from operations climbed 12% to $2.1 billion. The core story is a tale of two distinct trajectories: Cigna Healthcare and Evernorth's Specialty & Care segments posted massive double-digit profit growth, which entirely absorbed the anticipated earnings collapse in the traditional Pharmacy Benefit Services (PBS) division. By shedding its Medicare business and proactively repricing its PBM contracts, Cigna is executing a deliberate portfolio reshaping that is already yielding bottom-line results.
🐂 Bull Case
Evernorth's Specialty and Care Services is clearly the growth engine of the company, with Q1 pre-tax operating income accelerating 20% YoY to $1.07B on strong organic demand and accelerating biosimilar adoption.
Excluding the impact of the divested Medicare (HCSC) business, Cigna Healthcare revenues grew 8% YoY, driven by successful premium rate increases that outpaced medical cost trends, leading to an 18% jump in pre-tax profit.
🐻 Bear Case
Pharmacy Benefit Services (PBS) is undergoing a painful transition. Despite driving 11% higher revenue YoY, pre-tax profit plummeted 28% to $394 million as the company digests the margin impacts of its new rebate-free model and renegotiated mega-contracts.
Total pharmacy customers fell by 1.2 million sequentially (down 2% from Q4 2025) to 121.0 million, reflecting expected client transitions and ongoing turbulence in the health plan book.
⚖️ Verdict: 🟢
Bullish. Management telegraphed the 2026 PBM margin hit quarters ago, and they are proving their diversified model works by easily offsetting it with surging profits in Specialty Care and commercial healthcare. An EPS guidance raise in Q1 signals strong visibility.
Key Themes
Specialty & Care Services Outperformance
Accelerating. The Specialty & Care Services segment continues to outshine the rest of the portfolio. Revenue increased 6% to $25.4B, while pre-tax adjusted income jumped 20% YoY to $1.07B. Management cited strong organic specialty volume growth and increased adoption of generics and biosimilars, which lower costs for clients while providing a highly profitable fee-and-service stream for Cigna.
Pharmacy Benefit Services (PBS) Margin Collapse
Reversing. A glaring contradiction exists in the PBS data: Q1 segment revenue grew 11% to $33.0B, yet pre-tax adjusted income fell 28% YoY to $394M. The implied pre-tax margin collapsed to an exceptionally thin 1.2% (down from 1.8% a year ago). This is the direct result of the company transitioning to its 'rebate-free' model and absorbing the lower margin profile of massive renewed contracts (like Prime and DoD) that were secured in 2025.
Commercial Pricing Power Overcomes Medical Cost Trend
Accelerating. Cigna Healthcare (excluding the divested HCSC Medicare business) saw adjusted revenues rise 8% YoY to $11.47B. More importantly, pre-tax income rose 18% to $1.51B. This confirms that management's aggressive repricing efforts in the U.S. Employer and Individual and Family Plan (IFP) businesses are effectively staying ahead of the elevated macroeconomic medical cost trends that plagued the industry in 2025.
SG&A Efficiency
Stable. The adjusted SG&A expense ratio improved a full 100 basis points YoY, dropping to 4.8% in 26Q1 from 5.8% in 25Q1. While some of this is a mechanical benefit of the business mix shift post-Medicare divestiture, it demonstrates strong underlying cost control and directly supports the bottom-line earnings beat.
Customer Relationship Attrition
Decelerating. Total customer relationships declined 2% sequentially to 185.5 million. This was driven by a loss of 1.2 million pharmacy customers and lower membership in National Accounts within the medical book. While Cigna continues to grow in the Select and Middle Market employer tiers, the losses in large health plan and National Accounts signify fierce competitive pressure.
Other KPIs
Favorable compared to 82.2% in 25Q1. This significant optical improvement is heavily influenced by the divestiture of the higher-MCR Medicare business to HCSC, alongside actual margin improvement in the remaining commercial employer and individual books.
Improved from 43.0% at year-end 2025. The company remains on a steady glide path toward its long-term target of approximately 40%, signaling strong cash generation and prudent balance sheet management despite absorbing internal transition costs.
Up sequentially from $4.09 billion at the end of 2025. Management attributes this to typical stop-loss seasonality. Prior-year reserve development remained favorable at $188 million, though slightly lower than the $222 million recorded in 25Q1.
Guidance
Accelerating. Raised by $0.10 from prior guidance. This represents an expected YoY growth of at least 1.7% from 2025's $29.84. While modest, it proves the company can grow earnings despite taking the multi-billion dollar PBM transition hit in 2026.
Accelerating. Guidance raised by $25 million from previous estimates, indicating increased confidence in commercial pricing and utilization trends post-Medicare divestiture.
Decelerating YoY. Maintained from prior guidance. Represents an expected decline from 2025's $7.22B, entirely driven by the planned margin reset in the Pharmacy Benefit Services division, offset by growth in Specialty.
Stable. Maintained from prior guidance. Given the exceptionally low 79.8% printed in Q1, this full-year guidance implies MCR will step up significantly in the back half of the year, likely due to seasonality and built-in prudence for medical cost inflation.
Key Questions
MCR Pacing vs Guidance
With Q1 MCR coming in at a remarkably low 79.8%, yet full-year guidance maintained at 83.7% to 84.7%, what specific seasonal factors or anticipated cost spikes are driving the implied steep deterioration for the remainder of 2026?
PBS Margin Trough
Pharmacy Benefit Services pre-tax margin collapsed to roughly 1.2% this quarter. Is Q1 representative of the absolute margin trough for the new rebate-free contracts, or should we expect similar or worse compression through Q2 and Q3?
National Accounts Attrition
You noted lower membership in National Accounts alongside the drop in pharmacy customers. Are you walking away from large accounts strictly due to pricing discipline, or are competitors actively undercutting the new rebate-free model?